In summary, we discovered and validated that the on-treatment dNLR measured on day 1 of cycle 2 during palbociclib treatment significantly predicts survival outcomes of patients with HR-positive, HER2-negative ABC. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.